A phase 1b study of trebananib plus paclitaxel (P) and trastuzumab (T) in patients (pts) with HER2+locally recurrent or metastatic breast cancer (MEW).

被引：0
|
作者：
Kaufman, Peter Andrew
Freyer, Gilles
Kemeny, Margaret
Goncalves, Anthony
Heinrich, Guy
Jerusalem, Maria
Stopeck, Alison
Vrindavanam, Nandagopal
Dalenc, Florence
Nanayakkara, Nuwan
Wu, Benjamin
Pickett-Gies, Cheryl Ann
Wildiers, Hans
机构：
[1] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
[2] Ctr Hosp Lyon Sud, Lyon, France
[3] Queens Hosp, Queens Canc Ctr, Jamaica, NY USA
[4] Inst Paoli Calmettes, Marseille, France
[5] Ctr Hosp Univ Sart Tilman Liege, Liege, Belgium
[6] Univ Liege, Liege, Belgium
[7] Univ Arizona, Ctr Canc, Tucson, AZ USA
[8] Signal Point Hem Onc, Middletown, OH USA
[9] Inst Claudius Regaud, Toulouse, France
[10] Quintiles, San Diego, CA USA
[11] Amgen Inc, Dept Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA
[12] Amgen Inc, Oncol Clin Dev, Thousand Oaks, CA 91320 USA
[13] Univ Hosp Leuven, Leuven, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.502
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
502
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 1b study of trebananib plus paclitaxel and trastuzumab or capecitabine and lapatinib in patients with HER2+locally recurrent or metastatic breast cancer
    Kaufman, Peter A.
    Freyer, Gilles
    Kemeny, Margaret
    Goncalves, Anthony
    Jerusalem, Guy
    Stopeck, Alison
    Vrindavanam, Nandagopal
    Dalenc, Florence
    Nanayakkara, Nuwan
    Wu, Benjamin
    Pickett-Gies, Cheryl A.
    Wildiers, Hans
    CANCER RESEARCH, 2015, 75
  • [2] Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
    Kaufman, Peter A.
    Wildiers, Hans
    Freyer, Gilles
    Kemeny, Margaret
    Goncalves, Anthony
    Jerusalem, Guy
    Stopeck, Alison
    Vrindavanam, Nandagopal
    Dalenc, Florence
    Nanayakkara, Nuwan
    Wu, Benjamin
    Pickett, Cheryl A.
    CLINICAL BREAST CANCER, 2019, 19 (01) : 47 - 57
  • [3] Phase Ib study of open-label AMG 386 plus paclitaxel (P) and trastuzumab (T) or capecitabine (C) and lapatinib (L) in patients (pts) with HER2+locally recurrent or metastatic breast cancer (MBC).
    Wildiers, Hans
    Goncalves, Anthony
    Kemeny, Margaret
    Swart, Rachel Elizabeth
    Freyer, Gilles
    Nanayakkara, Nuwan
    Wu, Benjamin
    Pickett-Gies, Cheryl Ann
    Kaufman, Peter Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
    Ian E. Krop
    Shanu Modi
    Patricia M. LoRusso
    Mark Pegram
    Ellie Guardino
    Betsy Althaus
    Dan Lu
    Alexander Strasak
    Anthony Elias
    Breast Cancer Research, 18
  • [5] Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
    Krop, Ian E.
    Modi, Shanu
    LoRusso, Patricia M.
    Pegram, Mark
    Guardino, Ellie
    Althaus, Betsy
    Lu, Dan
    Strasak, Alexander
    Elias, Anthony
    BREAST CANCER RESEARCH, 2016, 18
  • [6] Treatment of locally recurrent, unresectable or metastatic breast cancer with AMG 706 plus paclitaxel or docetaxel: results from a phase 1b study
    de Boer, R.
    Kaufman, P.
    White, S.
    Mainwaring, P.
    Koczwara, B.
    Ye, Y.
    Sun, Y.
    Parson, M.
    Braun, A.
    Kotasek, D.
    EJC SUPPLEMENTS, 2008, 6 (07): : 222 - 222
  • [7] A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer
    Shatsky, Rebecca A.
    Batra-Sharma, Hemali
    Helsten, Teresa
    Schwab, Richard B.
    Pittman, Emily I.
    Pu, Minya
    Weihe, Elizabeth
    Ghia, Emanuela M.
    Rassenti, Laura Z.
    Molinolo, Alfredo
    Cabrera, Betty
    Breitmeyer, James B.
    Widhopf II, George F.
    Messer, Karen
    Jamieson, Catriona
    Kipps, Thomas J.
    Parker, Barbara A.
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [8] Motesanib (AMG 706) in combination with paclitaxel or docetaxel: phase 1b study in patients with locally recurrent, unresectable or metastatic breast cancer
    Kaufman, P.
    de Boer, R.
    White, S.
    Mainwaring, P.
    Koczwara, B.
    Urquhart, L. M.
    Ye, Y.
    Sun, Y.
    Adewoye, H.
    Kotasek, D.
    EJC SUPPLEMENTS, 2009, 7 (02): : 269 - 269
  • [9] HER2CLIMB-04: Phase II trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+locally advanced or metastatic breast cancer with and without brain metastases
    Carey, L. A.
    Krop, I.
    Ramos, J.
    Feng, W.
    Hamilton, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S510 - S511
  • [10] Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
    Pistilli, B.
    Pluard, T.
    Urruticoechea, A.
    Farci, D.
    Kong, A.
    Bachelot, T.
    Chan, S.
    Han, H. S.
    Jerusalem, G.
    Urban, P.
    Robinson, D.
    Mouhaer, S. L.
    Tomaso, E. D.
    Massacesi, C.
    Saura, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : 357 - 364
12345